ImmuCell Corporation (ICCC)

Currency in USD
9.800
-0.250(-2.49%)
Real-time Data·
ICCC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.71010.000
52 wk Range
4.52012.100
Key Statistics
Prev. Close
10.05
Open
10
Day's Range
9.71-10
52 wk Range
4.52-12.1
Volume
31.89K
Average Volume (3m)
30.94K
1-Year Change
60.5768%
Book Value / Share
3.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICCC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

ImmuCell Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

ImmuCell Corporation Earnings Call Summary for Q2/2026

  • ImmuCell Q2 2026 revenue rose 11.5% to $7.18M; net income tripled to $1.8M ($0.20/share), aided by $2M one-time legal settlement.
  • Gross margin fell sharply to 33.9% from 43.7% year-over-year due to manufacturing costs and product mix shifts, pressuring investor sentiment.
  • Domestic sales surged 27.7% to $6.2M driven by First Defense market share gains (15% to 19%), but international sales dropped 38.9% to $1M.
  • Company plans $8M capacity expansion through 2027 to triple output and cut processing time from 2-3 months to under one month.
  • Stock fell 5.64% to $10.285 despite strong results; InvestingPro flags shares as overvalued after 77% year-to-date gain.
Last Updated: 2026-08-14, 09:42 a/m
Read Full Transcript

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
0.20 / --
Revenue / Forecast
7.18M / --
EPS Revisions
Last 90 days

ICCC Income Statement

Compare ICCC to Peers and Sector

Metrics to compare
ICCC
Peers
Sector
Relationship
P/E Ratio
115.5x−2.8x−0.4x
PEG Ratio
−1.84−0.040.00
Price/Book
2.9x2.3x2.6x
Price / LTM Sales
3.0x77.5x3.1x
Upside (Analyst Target)
-126.6%47.9%
Fair Value Upside
Unlock7.2%6.3%Unlock

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Employees
73

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
462.29K5.11%4.65M
Other Institutional Investors
2.68M29.61%26.92M
Public Companies & Retail Investors
5.91M65.28%59.35M
Total
9.05M100.00%90.92M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
SRK Capital, LLC5.55%502,2585,048
SRK Fund I, LP5.55%502,2585,048

People Also Watch

7.34
SVCO
+1.10%
26.540
PPIH
-1.04%
31.735
CUE
-7.21%
68.12
LGN
+2.63%
104.86
MLAB
-1.11%

FAQ

What Is the ImmuCell (ICCC) Stock Price Today?

The ImmuCell stock price today is 9.800 USD.

What Stock Exchange Does ImmuCell Trade On?

ImmuCell is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ImmuCell?

The stock symbol for ImmuCell is "ICCC."

What Is the ImmuCell Market Cap?

As of today, ImmuCell market cap is 88.660M USD.

What Is ImmuCell's Earnings Per Share (TTM)?

The ImmuCell EPS (TTM) is 0.075.

When Is the Next ImmuCell Earnings Date?

ImmuCell will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is ICCC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has ImmuCell Stock Split?

ImmuCell has split 1 times.

How Many Employees Does ImmuCell Have?

ImmuCell has 73 employees.

What is the current trading status of ImmuCell (ICCC)?

As of Aug 17, 2026, ImmuCell (ICCC) is trading at a price of 9.800 USD, with a previous close of 10.050 USD. The stock has fluctuated within a day range of 9.710 USD to 10.000 USD, while its 52-week range spans from 4.520 USD to 12.100 USD.

What Is the ICCC Premarket Price?

ICCC's last pre-market stock price is 9.690 USD. The pre-market share volume is 1,550.000, and the stock has decreased by -0.360, or -3.580%.

What Is the ICCC After Hours Price?

ICCC's last after hours stock price is 9.790 USD, the stock has decreased by -0.260, or -2.590%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.